-
Something wrong with this record ?
Non-persistence with multiple secondary prevention medications for peripheral arterial disease among older hypertensive patients
M. Wawruch, M. Petrova, D. Celovska, SD. Alfian, T. Tesar, J. Murin, M. Trnka, T. Paduch, E. Aarnio
Status not-indexed Language English Country Switzerland
Document type Journal Article
NLK
Directory of Open Access Journals
from 2010
Free Medical Journals
from 2010
PubMed Central
from 2010
Europe PubMed Central
from 2010
Open Access Digital Library
from 2010-01-01
Open Access Digital Library
from 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2010
- Publication type
- Journal Article MeSH
INTRODUCTION: The benefit of secondary prevention in hypertensive patients with peripheral arterial disease (PAD) is based on continual simultaneous taking of statins, antiplatelet agents and antihypertensive agents, preferably angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs). Our study was aimed at a) the analysis of the extent of non-persistence with multiple medication classes, and b) identifying factors associated with the likelihood of non-persistence. METHODS: In our cohort study, 3,401 hypertensive patients (1,853 females and 1,548 males) aged ≥65 years treated simultaneously with statins, antiplatelet agents and ACEIs/ARBs and in whom PAD was newly diagnosed during 2012 were analysed. A patient was classified as non-persistent when he/she was non-persistent with at least one of the three analysed medication classes. The most important characteristics associated with the probability of non-persistence were identified using the Cox regression. RESULTS: At the end of the follow-up period (mean length 1.8 years), 1,869 (55.0%) patients (including 1,090 females and 779 males) were classified as non-persistent. In the whole study cohort, factors associated with non-persistence were female sex, atrial fibrillation, and being a new user of at least one of the analysed medication classes; in males, they were university education, atrial fibrillation, and epilepsy, and, in females, being a new user. CONCLUSION: Identification of sex differences in factors associated with non-persistence makes it possible to determine the groups of patients in whom special attention should be paid to improving their persistence with a combination of medicines in order to ensure successful secondary prevention of PAD.
Department of Internal Medicine Faculty of Medicine Comenius University Bratislava Slovakia
School of Pharmacy University of Eastern Finland Kuopio Finland
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25008806
- 003
- CZ-PrNML
- 005
- 20250422095640.0
- 007
- ta
- 008
- 250408e20241218sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3389/fphar.2024.1464689 $2 doi
- 035 __
- $a (PubMed)39744138
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Wawruch, Martin $u Institute of Pharmacology and Clinical Pharmacology, Faculty of Medicine, Comenius University, Bratislava, Slovakia
- 245 10
- $a Non-persistence with multiple secondary prevention medications for peripheral arterial disease among older hypertensive patients / $c M. Wawruch, M. Petrova, D. Celovska, SD. Alfian, T. Tesar, J. Murin, M. Trnka, T. Paduch, E. Aarnio
- 520 9_
- $a INTRODUCTION: The benefit of secondary prevention in hypertensive patients with peripheral arterial disease (PAD) is based on continual simultaneous taking of statins, antiplatelet agents and antihypertensive agents, preferably angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs). Our study was aimed at a) the analysis of the extent of non-persistence with multiple medication classes, and b) identifying factors associated with the likelihood of non-persistence. METHODS: In our cohort study, 3,401 hypertensive patients (1,853 females and 1,548 males) aged ≥65 years treated simultaneously with statins, antiplatelet agents and ACEIs/ARBs and in whom PAD was newly diagnosed during 2012 were analysed. A patient was classified as non-persistent when he/she was non-persistent with at least one of the three analysed medication classes. The most important characteristics associated with the probability of non-persistence were identified using the Cox regression. RESULTS: At the end of the follow-up period (mean length 1.8 years), 1,869 (55.0%) patients (including 1,090 females and 779 males) were classified as non-persistent. In the whole study cohort, factors associated with non-persistence were female sex, atrial fibrillation, and being a new user of at least one of the analysed medication classes; in males, they were university education, atrial fibrillation, and epilepsy, and, in females, being a new user. CONCLUSION: Identification of sex differences in factors associated with non-persistence makes it possible to determine the groups of patients in whom special attention should be paid to improving their persistence with a combination of medicines in order to ensure successful secondary prevention of PAD.
- 590 __
- $a NEINDEXOVÁNO
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Petrova, Miriam $u Institute of Pharmacology and Clinical Pharmacology, Faculty of Medicine, Comenius University, Bratislava, Slovakia
- 700 1_
- $a Celovska, Denisa $u Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia
- 700 1_
- $a Alfian, Sofa D $u Department of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Bandung, Indonesia $u Center of Excellence in Higher Education for Pharmaceutical Care Innovation, Universitas Padjadjaran, Bandung, Indonesia
- 700 1_
- $a Tesar, Tomas $u Department of Organisation and Management of Pharmacy, Faculty of Pharmacy, Comenius University, Bratislava, Slovakia
- 700 1_
- $a Murin, Jan $u Department of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovakia
- 700 1_
- $a Trnka, Michal $u Institute of Medical Physics and Biophysics, Faculty of Medicine, Comenius University, Bratislava, Slovakia
- 700 1_
- $a Paduch, Tomas $u 2nd Department of Surgery, Center for Vascular Disease, St. Anne's University Hospital and Faculty of Medicine, Masaryk University, Brno, Czechia
- 700 1_
- $a Aarnio, Emma $u School of Pharmacy, University of Eastern Finland, Kuopio, Finland
- 773 0_
- $w MED00174597 $t Frontiers in pharmacology $x 1663-9812 $g Roč. 15 (20241218), s. 1464689
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39744138 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250408 $b ABA008
- 991 __
- $a 20250422095641 $b ABA008
- 999 __
- $a ok $b bmc $g 2306492 $s 1245881
- BAS __
- $a 3
- BAS __
- $a PreBMC-PubMed-not-MEDLINE
- BMC __
- $a 2024 $b 15 $c - $d 1464689 $e 20241218 $i 1663-9812 $m Frontiers in pharmacology $n Front Pharmacol $x MED00174597
- LZP __
- $a Pubmed-20250408